Santhera and ReveraGen Announce New 2.5-year Treatment Data with Vamorolone in Duchenne ...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Santhera and ReveraGen Announce New 2.5-year Treatment Data with Vamorolone in Duchenne ... Santhera Pharmaceuticals Holding AGApril 28, 2021 GMT Pratteln, Switzerland, April 28, 2021 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen Biopharma announce new clinical data of 2.5-year treatment outcome with vamorolone in patients with Duchenne muscular dystrophy (DMD). These Phase 2a long-term treatment data demonstrate a maintenance of treatment effect, equivalent to a delay of about two years ...